Navigation Links
Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
Date:12/21/2007

s not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients receiving VELCADE. Some of these events have been fatal. A higher proportion of these events have been reported in Japan. There have been rare reports of Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in patients receiving VELCADE. RPLS is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. VELCADE is associated with thrombocytopenia and neutropenia. There have been reports of gastrointestinal and intracerebral hemorrhage in association with VELCADE. Transfusions may be considered. Complete blood counts (CBC) should be frequently monitored during treatment with VELCADE. Rare cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions.

Integrated Safety Data: Safety data from phase 2 and 3 studies of single- agent VELCADE 1.3 mg/m2/dose twice weekly for 2 weeks followed by a 10-day rest period in 1163 patients with multiple myeloma (N=1008) and mantle cell lymphoma (N=155) were integrated and tabulated. In these studies, the safety profile of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma. In the integrated analysis, the most commonly reported adverse events were asthenic conditions (including fatigue, malaise, and weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy NEC
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Bear Stearns 20th Annual Healthcare Conference to Webcast Millennium Presentation
2. Synova Healthcare to Participate in Womens Health Care in the New Millennium Conference, as Retail Distribution for the Fem-V(R) Test Kit Expands
3. Statement by Bonnie J. Campbell, Former Attorney General of Iowa and Spokesperson for Atlantic Richfield Co., Millennium Holdings, LLC, NL Industries, Inc., and The Sherwin-Williams Company on the Jury Verdict Reached Today in the Thomas (Milwaukee) Case
4. 2007 Credit Suisse Healthcare Conference to Webcast Millennium Presentation
5. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
6. Millennium Biotechnologies Inc. Signs Five Year $20,000,000 Purchase Agreement with Provider Services Inc. of Cleveland, Ohio
7. Millennium Pharmaceuticals Announces Webcast of American Society of Hematology Investor Event
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
9. Global Med Technologies(R), Inc. Submits ElDorado Donor(TM) to FDA
10. Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
11. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)... After suffering from women,s hair loss for almost... and she,s sharing her progress and the secret beh...ugh the release of her video diaries which include... her treatment. , (PRWeb ...ferer Zsanett Siklosi has released the video diari...
(Date:11/23/2009)...TargetIndividualsintheRecommendedPriorityGroups ,...--TheDepartmentofHealthannouncedtodaytheywillcondu...eHealthCentersinDelaware,Lancaster,andLehighcounti...inewillbeadministeredforfreetoindividualsinthereco...hevaccine.Thedepartmentasksthatonlyindividualsinth...
(Date:11/23/2009)...care professionals enjoy a pay raise for a job wel...s for health care performance may actually backfir... performance ratings for 25 medical groups across ...unch of a statewide pay-for-performance program in... productivity. , Reporting in the December ed...
(Date:11/23/2009)...t woman to head the agency, said lives could be at...s) -- The fallout from last week,s controversial r...e mammogram testing for breast cancer continues, w...of Health advising women to ignore the guidelines....ause unequivocally this will increase the number o...
(Date:11/23/2009)...caretofinance"reform"isamoraloutrage ,, WASHI...eDemocratsmovedforwardtobeginthedebateontheirhealt...pporterstronggrassrootssenioradvocacygroup,iscalli...testthemassivecutstoMedicare.RetireSafePresidentTh...issuesliketaxes,abortion,andimmigration,whilethesi...
Breaking Medicine News(10 mins):Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 3Health News:Pennsylvania Department of Health Announces Additional H1N1 Vaccination Clinics in Delaware, Lancaster, Lehigh Counties 2Health News:Medical 'pay for performance' programs help improve care -- but not always, study finds 2Health News:Medical 'pay for performance' programs help improve care -- but not always, study finds 3Health News:Women Should Ignore New Mammogram Guideline, Ex-NIH Chief Says 2Health News:Women Should Ignore New Mammogram Guideline, Ex-NIH Chief Says 3Health News:RetireSafe Calls on Seniors to Grab their Bullhorns to Save Medicare from Rationed Care 2
...enwood Systems, LLC ( http://www.GlenwoodSystems.c...h seamlessly integrates EMR and Practice Manage...ess. The product has been designed to reduce the ... Waterbury, CT (Vocus) February 26...
... affordable High Voltage Piezo Amplifier (QPA200) ...l applications, and to facilitate transducer evalu... Medford, MA (PRWEB) February 26, 2009 -- P...coustically cancel noise, or to replace solenoid v...
...n the retina that is responsible for maintaining t...as been imaged in a living retina for the first ti...yer could help doctors identify the onset of many ... ., "Our goal is to figure out why macular degene...
...harmaNet Development Group, Inc. (the "Company") (...evelopment services, today reported preliminary ne... 2008, of $1.6 million, or $0.08 per diluted share...provided in this press release is subject to recor...
...or February 26, 2009 at 10:00 a.m. EST , , , EA...ls, Inc. (Nasdaq: SVNT ) today reported financia...mber 31, 2008. For the fourth quarter of 2008, th...ad a net loss of $84.2 million, or $1.57 per share...
...ookings and continued positive cash flow from oper... AMCS ), a leader in radiology and medical image...ted unaudited financial results for the fourth qua...evenue : Total revenue for the fourth quarter of 2...
Other Medicine News:Health News:Glenwood Systems, LLC Improves Medical Billing Process with GlaceComplete 2Health News:Glenwood Systems, LLC Improves Medical Billing Process with GlaceComplete 3Health News:Amped Up Piezos Are On The Move - Driving Piezos with an Affordable High Voltage Piezo Amplifier QPA200 2Health News:Amped Up Piezos Are On The Move - Driving Piezos with an Affordable High Voltage Piezo Amplifier QPA200 3Health News:'Dark cells' of living retina imaged for the first time 2Health News:'Dark cells' of living retina imaged for the first time 3Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 2Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 3Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 4Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 5Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 6Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 7Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 8Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 9Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 10Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 11Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 12Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 13Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 14Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 15Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 16Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 17Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 2Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 3Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 4Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 5Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 6Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 7Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 8Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 9Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 2Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 3Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 4Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 5Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 6
(Date:11/23/2009)...ingtheFDAapprovalsoftwonewtherapiesforNon-Hodgkin,...atedtoincludeofatumumab(Azerra(TM),GlaxoSmithKline...leukemia(CLL)andromidepsin(Istodax(R),GloucesterPh...cutaneousT-celllymphoma(CTCL). ,, FORTWASHINGTO...pprovalshavepromptedtheNationalComprehensiveCancer...
(Date:11/23/2009)...K,Nov.23/PRNewswire/--Reportlinker.comannouncestha.... ,, AnesthesiaDisposables-AWorldMarketReview ...thesia-Disposables---A-World-Market-Review.html#ut...aign=prnewswire ,, Globalgeneralanesthesiad...ration.Despitetheconsiderablerisewitnessedingenera...
(Date:11/23/2009)...DLANDS,Texas,Nov.23/PRNewswire-FirstCall/-- Lexico...aythattop-linedatafromitsPhase2clinicalstudywith L...syndrome(IBS)willbepresentedatGASTRO2009inLondonth...improvementinIBSsymptoms,willbepresentedbyDr. Phil...evelopment,onNovember25,2009at2:30pmlocaltimeatthe...
Breaking Medicine Technology:NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 2NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 3Reportlinker Adds Anesthesia Disposables - A World Market Review 2Reportlinker Adds Anesthesia Disposables - A World Market Review 3Reportlinker Adds Anesthesia Disposables - A World Market Review 4Reportlinker Adds Anesthesia Disposables - A World Market Review 5Reportlinker Adds Anesthesia Disposables - A World Market Review 6Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009 2Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009 3Galil Medical Announces Establishment of Global Headquarters in Minneapolis MN 5093 1Galil Medical Announces Establishment of Global Headquarters in Minneapolis MN 5093 2Michael J Fox Foundation Funded Team Pursuing Glutamate Based Treatment for Parkinsons Disease Hits Major Milestone 5090 1Michael J Fox Foundation Funded Team Pursuing Glutamate Based Treatment for Parkinsons Disease Hits Major Milestone 5090 2GenVec Receives National Cancer Institute Grant to Expand Cancer Program 5087 1GenVec Receives National Cancer Institute Grant to Expand Cancer Program 5087 2
... international hub for collaborative research, bio...e Wayne State University research and technology...mmercialization lab in Michigan. The Wayne County ...ld of Wayne County Executive Robert Ficano, who pu...500-square-foot stem cell research facility in his...
...or less , , PRINCETON, N.J., Feb. 13 Derma Scie...er of advanced wound care products, announced toda... case series on eleven non-healing venous leg ulce...ile being managed with such therapeutic modalities...l dressings, antibiotic therapy, and hyperbaric ox...
Other Medicine Technology:Wayne County Partners With TechTown to Launch Global Stem Cell 'Innovation and Commercialization Lab' 2MEDIHONEY(TM) Dressings Shown to Help Improve Outcomes of Non-Healing Venous Leg Ulcers in Recent Case Series 2MEDIHONEY(TM) Dressings Shown to Help Improve Outcomes of Non-Healing Venous Leg Ulcers in Recent Case Series 3
Gentamicin, 50 mg/ml
GENTAMICIN SULFATE, 1000X
...e is effective against gram positive and gram nega...ng with bacterial protein synthesis by binding to ...g concentration of 50 mg/L is generally non-toxic ...entler alternative to penicillin and steptomycin. ...
Gibco Gentamicin Reagent Solution (10 mg/ml) liquid
Medicine Products: